Evidence map›Paper›PMID 42334733›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026

In vitro activity of β-lactamase inhibitors avibactam, relebactam and vaborbactam in combination with aztreonam against metallo-β-lactamase producing Escherichia coli clinical isolates.

Clément Viguier, Samanta Freire, Maxime Bouvier, Christophe Le Terrier, Laurent Poirel, NARA Network, Patrice Nordmann

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Clément ViguierEmerging Antibiotic Resistance Unit, Department of Medicine, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, CH-1700, Fribourg, Switzerland.ORCID http://orcid.org/0000-0002-3270-178X
Samanta FreireEmerging Antibiotic Resistance Unit, Department of Medicine, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, CH-1700, Fribourg, Switzerland.
Maxime BouvierEmerging Antibiotic Resistance Unit, Department of Medicine, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, CH-1700, Fribourg, Switzerland.
Christophe Le TerrierEmerging Antibiotic Resistance Unit, Department of Medicine, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, CH-1700, Fribourg, Switzerland.ORCID http://orcid.org/0000-0002-5455-5576
Laurent PoirelEmerging Antibiotic Resistance Unit, Department of Medicine, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, CH-1700, Fribourg, Switzerland. laurent.poirel@unifr.ch.ORCID http://orcid.org/0000-0001-5160-5286
NARA Network
Patrice NordmannEmerging Antibiotic Resistance Unit, Department of Medicine, Medical and Molecular Microbiology, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, CH-1700, Fribourg, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aztreonam-avibactam (ATM-AVI) is one of the few remaining therapeutic options for infections caused by metallo-β-lactamase (MBL)-producing Enterobacterales, yet resistance is increasingly reported. Alternative strategies are therefore critically needed. We investigated the in vitro activity of aztreonam in combination with three marketed β-lactamase inhibitors (avibactam, vaborbactam, relebactam) against 48 well-characterized ATM-resistant MBL-producing Escherichia coli, including 34 ATM-AVI-resistant isolates. Among ATM-AVI-susceptible isolates, ATM-relebactam and ATM-vaborbactam showed reduced activity compared with ATM-AVI (MIC

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsAztreonambeta-Lactamase InhibitorsBoronic AcidsEscherichia colibeta-LactamasesEscherichia coli InfectionsHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsavibactamAzabicyclo CompoundsAztreonambeta-Lactamase Inhibitorsbeta-LactamasesBoronic AcidsrelebactamvaborbactamAztreonam-avibactamMetallo-beta-lactamaseRelebactamVaborbactamβ‑lactam/β‑lactamase inhibitor combinations

Identifiers

PMID42334733

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.